News & Updates

The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.

The orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α (HIF-1α) GB004 appears to improve disease activity in patients with ulcerative colitis, with the drug being well-tolerated, according to the results of a phase Ib trial.

The novel highly selective mineralocorticoid receptor blocker esaxerenone holds promise in the treatment of nocturnal hypertension, yielding substantial reductions in night-time blood pressure (BP), especially in Japanese patients with a riser pattern, as well as in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, according to a post hoc analysis of a phase III study.

In individuals with psoriatic arthritis (PsA) who have inadequate response or intolerance to ≥1 csDMARD*, the monoclonal antibody risankizumab significantly improved manifestations of PsA, according to the 24-week findings of the phase III KEEPsAKE 1 trial.

Treatment with apremilast is effective in mild-to-moderate plaque psoriasis and has a consistent safety profile, results of a phase III study have shown.

Individuals with metabolic syndrome who are hospitalized for COVID-19 may have a greater risk for more severe COVID-19 disease, including an elevated risk of in-hospital mortality, acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) admission, a recent prospective study showed.

The risk for hip fracture slightly increases following osteoporosis drug holidays after long-term therapy with risedronate compared with alendronate, a study has found, adding that future research must examine how best to lessen such risk.

The nonsteroidal topical aryl hydrocarbon receptor (AHR)-modulating agent tapinarof 1% trumped a vehicle control cream in reducing the severity and manifestations of plaque psoriasis, according to the phase III PSOARING 1 and 2 trials.